Agozzino L, Thomopoulos K, Esposito S, Agozzino M, De Vivo F, Maiello C, Cotrufo M
Istituto di Anatomia ed Istologia Patologica, II Università degli Studi di Napoli.
Pathologica. 1999 Apr;91(2):89-100.
From January 1988 through October 1997, 167 cardiac transplants were performed. 1246 endomyocardial biopsies (EMBs) from 138 cardiac allograft recipients were investigated and graded according to the Working Formulation (WF) criteria. The specimens were inadequate in 44 EMBs (3.5%), while 598 (48%) showed no rejection. The grade of rejection was: mild (grade 1A and 1B) in 531 EMBs (42.6%), mild/moderate (grade 2) in 38 (3.1%), and moderate (grade 3A and 3B) in 35 (2.8%). The indications for transplantation were: dilated cardiomyopathy (46.1%); ischemic disease (37.1%); valvular disease (12%); hypertrophic cardiomyopathy (1.8%); myocarditis (1.2%); congenital cardiopathy (0.6%), restrictive cardiomyopathy (0.6%) and chronic rejection (0.6%). The most reliable histologic feature of acute rejection was the myocyte necrosis or damage in presence of pironinophilic mononuclear cell infiltrate, so our protocol requires multifocal or diffuse myocyte damage (rejection grade 3A and 3B) to perform an additional treatment, which was required in 35 cases (2.8%). An intermediate grade mild/moderate 2, was introduced from the WF to classify the EMBs in which the myocyte necrosis was scant or not clear; this grade in our series generally resolves without any additional treatment; in order to monitor the rejection another EMB was performed 5 days after in these patients. The EMBs showed also the following lesions other than acute rejection: Quilty A (79 patients; 57.25%), Quilty B (24 pts; 17.39%), early ischemic necrosis (43 pts; 31.15%) and late ischemic necrosis (5 pz; 3.62%). Quilty B and late ischemic necrosis were correlated with acute rejection (grade 2), furthermore the patients with graft vascular disease showed 3 or more episodes of acute rejection. These findings confirm the relationship between acute and chronic rejection. Furthermore, a relationship between chronic rejection (4 pts) and infection from hepatitis C (antibodies positive 3 pts/4) and cytomegalovirus (antibodies positive 4 pts/4) was found in our series. In the follow-up period (117 months), a 30.72% death rate was recorded; the main causes of death were: early failure of the transplanted heart (30 pts) in 4 of them associated with pulmonary hypertension, infections (6 pts), sudden death (4 pts), graft's vasculopathy (4 pts), acute pancreatitis (1 pts) pulmonary embolism (1 pts), lung (1 pts) and ovary (1 pts) carcinoma, acute rejection (1 pts), others (2 pts). In the early period (< 1 month), the most frequent cause of death was the early failure of the transplanted heart, while in the late period (> 1 year) the chronic rejection following by sudden death and tumours. The actuarial survival curve drops to 83.13% after the first post-operative month, abates to 75.30 at the end of the first year, and progressively decreases to 70.48% at the end of the fifth follow-up year. The mortality rate was 38.7% in pts transplanted for ischemic disease and 24.7% for dilated cardiomyopathy. Cardioplegia seems to play an important role in the success of the heart transplant.
从1988年1月至1997年10月,共进行了167例心脏移植手术。对138例心脏移植受者的1246份心内膜心肌活检(EMB)标本进行了研究,并根据工作配方(WF)标准进行分级。44份EMB标本(3.5%)不合格,而598份(48%)未显示排斥反应。排斥反应分级为:轻度(1A级和1B级)531份EMB(42.6%),轻度/中度(2级)38份(3.1%),中度(3A级和3B级)35份(2.8%)。移植指征为:扩张型心肌病(46.1%);缺血性疾病(37.1%);瓣膜病(12%);肥厚型心肌病(1.8%);心肌炎(1.2%);先天性心脏病(0.6%),限制性心肌病(0.6%)和慢性排斥反应(0.6%)。急性排斥反应最可靠的组织学特征是在嗜派洛宁单核细胞浸润的情况下出现心肌细胞坏死或损伤,因此我们的方案要求多灶性或弥漫性心肌细胞损伤(排斥反应3A级和3B级)时进行额外治疗,35例(2.8%)需要进行额外治疗。从WF引入了中度轻度/中度2级,以对心肌细胞坏死较少或不明显的EMB进行分类;在我们的系列中,该级别通常无需任何额外治疗即可缓解;为了监测排斥反应,在这些患者中于5天后再次进行EMB检查。EMB还显示出除急性排斥反应外的以下病变:奎尔蒂A(79例患者;57.25%),奎尔蒂B(24例患者;17.39%),早期缺血性坏死(43例患者;31.15%)和晚期缺血性坏死(5例患者;3.62%)。奎尔蒂B和晚期缺血性坏死与急性排斥反应(2级)相关,此外,患有移植物血管疾病的患者出现3次或更多次急性排斥反应。这些发现证实了急性和慢性排斥反应之间的关系。此外,在我们的系列中发现慢性排斥反应(4例患者)与丙型肝炎感染(抗体阳性3例/4例)和巨细胞病毒感染(抗体阳性4例/4例)之间存在关联。在随访期(117个月),记录的死亡率为30.72%;主要死亡原因是:移植心脏早期功能衰竭(30例患者),其中4例与肺动脉高压相关,感染(6例患者),猝死(4例患者),移植物血管病变(4例患者),急性胰腺炎(1例患者),肺栓塞(1例患者),肺癌(1例患者)和卵巢癌(1例患者),急性排斥反应(1例患者),其他(2例患者)。在早期(<1个月),最常见的死亡原因是移植心脏早期功能衰竭,而在晚期(>1年),慢性排斥反应继之以猝死和肿瘤。术后第一个月后精算生存曲线降至83.13%,第一年末降至75.30%,在第五次随访年末逐渐降至70.48%。因缺血性疾病接受移植的患者死亡率为38.7%,扩张型心肌病患者死亡率为24.7%。心脏停搏似乎在心脏移植成功中起重要作用。